Your browser doesn't support javascript.
loading
Molecular basis of polycomb group protein-mediated fetal hemoglobin repression.
Qin, Kunhua; Lan, Xianjiang; Huang, Peng; Saari, Megan S; Khandros, Eugene; Keller, Cheryl A; Giardine, Belinda; Abdulmalik, Osheiza; Shi, Junwei; Hardison, Ross C; Blobel, Gerd A.
Afiliación
  • Qin K; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Lan X; Department of Systems Biology for Medicine, School of Basic Medical Sciences, Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Huang P; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Saari MS; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Khandros E; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Keller CA; Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, State College, PA.
  • Giardine B; Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, State College, PA.
  • Abdulmalik O; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Shi J; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Hardison RC; Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, State College, PA.
  • Blobel GA; Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
Blood ; 141(22): 2756-2770, 2023 06 01.
Article en En | MEDLINE | ID: mdl-36893455
ABSTRACT
The switch from fetal hemoglobin (HbF) to adult hemoglobin (HbA) is a paradigm for developmental gene expression control with relevance to sickle cell disease and ß-thalassemia. Polycomb repressive complex (PRC) proteins regulate this switch, and an inhibitor of PRC2 has entered a clinical trial for HbF activation. Yet, how PRC complexes function in this process, their target genes, and relevant subunit composition are unknown. Here, we identified the PRC1 subunit BMI1 as a novel HbF repressor. We uncovered the RNA binding proteins LIN28B, IGF2BP1, and IGF2BP3 genes as direct BMI1 targets, and demonstrate that they account for the entirety of BMI1's effect on HbF regulation. BMI1 functions as part of the canonical PRC1 (cPRC1) subcomplex as revealed by the physical and functional dissection of BMI1 protein partners. Lastly, we demonstrate that BMI1/cPRC1 acts in concert with PRC2 to repress HbF through the same target genes. Our study illuminates how PRC silences HbF, highlighting an epigenetic mechanism involved in hemoglobin switching.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemoglobina Fetal / Complejo Represivo Polycomb 1 Tipo de estudio: Clinical_trials Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Panamá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Hemoglobina Fetal / Complejo Represivo Polycomb 1 Tipo de estudio: Clinical_trials Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article País de afiliación: Panamá